MX2020009278A - Ensayos para detectar la neurodegeneración. - Google Patents

Ensayos para detectar la neurodegeneración.

Info

Publication number
MX2020009278A
MX2020009278A MX2020009278A MX2020009278A MX2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A MX 2020009278 A MX2020009278 A MX 2020009278A
Authority
MX
Mexico
Prior art keywords
methods
tests
antibodies
neurodegeneration
detect
Prior art date
Application number
MX2020009278A
Other languages
English (en)
Inventor
Hartmuth Christian Kolb
Gallen Triana-Baltzer
John Randall Slemmon
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020009278A publication Critical patent/MX2020009278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan métodos para medir la cantidad de proteína tau p217+ individual o grupalmente fosforilada en una muestra; además, se proporcionan métodos para detectar o diagnosticar tauopatías, métodos para determinar la eficacia de un tratamiento de una tauopatía, y métodos para determinar si un sujeto es adecuado para la terapia con anticuerpo anti-tau p217+. También se describen anticuerpos para usar en los métodos y kits que comprenden los anticuerpos.
MX2020009278A 2018-03-05 2019-03-04 Ensayos para detectar la neurodegeneración. MX2020009278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638524P 2018-03-05 2018-03-05
PCT/IB2019/051747 WO2019171258A1 (en) 2018-03-05 2019-03-04 Assays to detect neurodegeneration

Publications (1)

Publication Number Publication Date
MX2020009278A true MX2020009278A (es) 2021-01-08

Family

ID=67768541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009278A MX2020009278A (es) 2018-03-05 2019-03-04 Ensayos para detectar la neurodegeneración.

Country Status (16)

Country Link
US (3) US10591492B2 (es)
EP (1) EP3762414A4 (es)
JP (3) JP7399096B2 (es)
KR (3) KR20240150533A (es)
CN (2) CN120329431A (es)
AU (2) AU2019232630B2 (es)
BR (1) BR112020018193A2 (es)
CA (1) CA3093198A1 (es)
EA (1) EA202092087A1 (es)
IL (1) IL277077A (es)
JO (1) JOP20200216A1 (es)
MA (1) MA53338A (es)
MX (1) MX2020009278A (es)
PH (1) PH12020551371A1 (es)
SG (1) SG11202008574VA (es)
WO (1) WO2019171258A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092088A1 (ru) 2018-03-05 2020-11-13 Янссен Фармацевтика Нв Антитела анти-phf-тау и их применение
CA3297188A1 (en) * 2019-05-31 2026-03-02 Eli Lilly And Company Compounds and methods targeting human tau
EP4040153A4 (en) * 2019-09-30 2023-07-26 Nipro Corporation PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE
MX2022012628A (es) * 2020-04-08 2023-01-11 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos.
KR20230037647A (ko) * 2020-07-14 2023-03-16 얀센 파마슈티카 엔.브이. 타우병증 또는 아밀로이드성 질환을 검출하기 위한 혈액-기반 검정
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
CN116635414A (zh) * 2021-02-19 2023-08-22 卫材R&D管理有限公司 抗pt217 tau抗体
CN117460954A (zh) * 2021-03-31 2024-01-26 华盛顿大学 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况
WO2023056410A1 (en) * 2021-10-01 2023-04-06 Integrated Neurologics LLC Methods and devices for detecting cerebrospinal fluid leakage
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
JP7450995B1 (ja) 2023-04-13 2024-03-18 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置
WO2024214588A1 (ja) * 2023-04-13 2024-10-17 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置
WO2025037271A1 (en) * 2023-08-17 2025-02-20 Janssen Pharmaceutica Nv Plasma assay for detecting cns-derived tau peptides
AU2024367335A1 (en) * 2023-10-27 2026-05-14 The University Of Queensland Anti-tau therapeutic antibody for ad and tauopathies
WO2025099460A1 (en) * 2023-11-10 2025-05-15 Cambridge Enterprise Limited Calibrator
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026029079A1 (ja) * 2024-07-31 2026-02-05 富士レビオ株式会社 リン酸化タウタンパク質の測定方法およびリン酸化タウタンパク質の測定キット

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
AU698383B2 (en) 1993-12-21 1998-10-29 Innogenetics N.V. Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
CN1230174C (zh) 1999-07-06 2005-12-07 伊莱利利公司 治疗偏头痛的选择性iGluR5受体拮抗剂
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PT2794654T (pt) 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
WO2014011972A1 (en) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
HRP20201422T1 (hr) * 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
NZ727020A (en) * 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
UA128752C2 (uk) * 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3212630A1 (en) * 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules

Also Published As

Publication number Publication date
US20190271710A1 (en) 2019-09-05
EP3762414A4 (en) 2022-01-05
JP2025186346A (ja) 2025-12-23
BR112020018193A2 (pt) 2021-02-02
US20200408781A1 (en) 2020-12-31
EP3762414A1 (en) 2021-01-13
PH12020551371A1 (en) 2021-08-23
WO2019171258A1 (en) 2019-09-12
MA53338A (fr) 2022-01-05
JP2021517239A (ja) 2021-07-15
US20200182888A1 (en) 2020-06-11
JOP20200216A1 (ar) 2020-09-03
KR20240150533A (ko) 2024-10-15
CN112105640A (zh) 2020-12-18
CA3093198A1 (en) 2019-09-12
KR20200130354A (ko) 2020-11-18
JP2024037794A (ja) 2024-03-19
KR102716144B1 (ko) 2024-10-10
US10591492B2 (en) 2020-03-17
AU2019232630B2 (en) 2025-11-13
JP7399096B2 (ja) 2023-12-15
AU2019232630A1 (en) 2020-09-24
CN112105640B (zh) 2025-03-04
IL277077A (en) 2020-10-29
EA202092087A1 (ru) 2020-11-17
SG11202008574VA (en) 2020-10-29
KR20250042856A (ko) 2025-03-27
AU2026200694A1 (en) 2026-02-19
US10976325B2 (en) 2021-04-13
CN120329431A (zh) 2025-07-18

Similar Documents

Publication Publication Date Title
PH12020551371A1 (en) Assays to detect neurodegeneration
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
BR112015021199A2 (pt) método para determinar se uma infeção é bacteriana e/ou viral, dispositivo de fluxo lateral para detecção de um analito em uma amostra, e, dispositivo para detecção de um marcador bacteriano e/ou viral em uma amostra
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
MX389083B (es) Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
BR112018016337A2 (pt) anticorpos monoclonais da proteína ns1 de vírus antidengue
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
DE60300339D1 (de) Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
PT1776587E (pt) Utilização de c3a e seus derivados como biomarcador para o adenoma e/ou carcinoma colorrectal; processos de diagnóstico e ensaios utilizando os mesmos
MX2023007633A (es) Inmunoensayo diva de la fiebre porcina africana.
MX2021003577A (es) Uso de niveles trem-1 soluble para identificar sujetos susceptibles de responder a una terapia antiinflamatoria.
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
BR112016021714A2 (pt) imunoensaio e anticorpos para a detecção de cromogranina a
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
MX2022000882A (es) Componente de deteccion de antigenos de grupo sanguineo.
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
BR112018076005A2 (pt) anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
WO2014126487A3 (en) Diagnosis and detection of dengue virus infection using chicken egg antibodies
DE602006015702D1 (de) Unterscheidung zwischen baktiereller meningitis und viraler meningitis
WO2019170545A8 (en) Means for the quantitative determination of an analyte concentration in a patient's urine sample
MX2022002328A (es) Metodos de un solo paso, kits, y sistemas para la medicion de concentraciones de bilirrubina no enlazada en fluidos biologicos.
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome